secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001628280-25-052008
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus Q3 revenue $11.6M (+57% YoY); net loss $41.3M on preferred conversion; reaffirms 50% FY growth
--------------------------------------------------------------------------------

- Revenue $11.6M, up 57% YoY and 3% sequentially; all from TriNav liver embolization.
- Gross margin 84% vs 86% prior year; operating loss $9.0M vs $8.7M.
- Net loss attributable to common $41.3M ($0.96 EPS) due to $30.5M preferred conversion charge.
- Adjusted EBITDA loss improved to $5.4M from $7.2M; cash $22.7M with runway to positive adj. EBITDA.
- Reaffirmed FY2025 revenue growth of at least 50%; initiated GAE trial for knee OA; published thyroid embolization data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000162828025052008/0001628280-25-052008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000162828025052008/tlsi-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-052008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer